



ASX Announcement | 9 September 2019  
Althea Group Holdings (ASX:AGH)

## Althea registers 1,925 Australian patients

### INVESTMENT HIGHLIGHTS:

- 1,925 patients have now been prescribed Althea medicinal cannabis products in Australia, with 296 Healthcare Professionals actively prescribing Althea medicinal cannabis
- 392 patients were added in August, representing the largest number of new patients prescribed Althea products in a single month at a rate of approximately 18 new patients per business day
- The Australian medicinal cannabis market increased at its highest rate so far in August, adding 2,893 TGA SAS Category B approvals<sup>1</sup>


9 September 2019: **Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company')** is pleased to provide the following update regarding the uptake of its medicinal cannabis products in Australia.

### AUGUST A RECORD-BREAKING MONTH FOR PATIENT UPTAKE

Althea welcomed 392 new patients in August at a rate of approximately 18 patients per business day, representing the largest number of new patients to be prescribed Althea products in a single month.

In addition, there are now 296 Australian Healthcare Professionals ('HCPs') who have prescribed Althea's products.


**Chart 1: Patient Growth**



<sup>1</sup> <https://www.tga.gov.au/access-medicinal-cannabis-products-1>



**Chart 2: HCP Growth**



**ALTHEA CEO JOSH FEGAN SAID:** “Althea continues to facilitate a growing number of Australian doctors to prescribe Althea medicinal cannabis to patients all over the country, with thousands of Australians now benefiting from treatment with Althea medicinal cannabis. Althea is demonstrating that the medicinal cannabis industry in Australia has enormous potential – especially with the support of the medical community which continues to gain momentum. Althea is focussed on medical education and this is proving that by working closely with Healthcare Professionals, medicinal cannabis can reach an ever-increasing number of patients.”


### MEDICINAL CANNABIS APPLICATIONS ON THE RISE

Althea’s growth follows the increase in Therapeutic Good Administration (‘TGA’) Special Access Scheme Category B (‘SAS B’) applications in Australia. The Australian medicinal cannabis market increased at its highest rate so far in August, adding 2,893 TGA SAS B approvals.

The rapid uptake of Althea’s products is being driven by the Company’s strategy comprised of: an on-the-ground Medical Science Liaison team; *Althea Concierge*, the Company’s proprietary technology platform which streamlines the application process for HCPs prescribing medicinal cannabis; and its secondary channel of clinic partners in Australia.



**Chart 3: SAS B Growth**



-ENDS-

**Althea Group Holdings Limited (ASX:AGH)**

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (**ASX:AGH**). Althea also offers a range of education, access and management services to support eligible patients and Healthcare Professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: [www.althea.life](http://www.althea.life)

**FOR FURTHER INFORMATION, PLEASE CONTACT:**

**Althea**  
**Josh Fegan**  
 CEO & Managing Director  
**M: 1300 70 20 20**  
**E: contact@althea.life**

**Media Enquiries**  
**Julia Maguire**  
 The Capital Network  
**M: +61 419 815 386**  
**E: julia@thecapitalnetwork.com.au**

**Australian Investors**  
**PAC Partners Securities**  
**M: 03 9114 7401**  
**E: enquiries@pacpartners.com.au**